Allergen-specific immunotherapy of allergy and asthma: Current and future trends

Expert Review of Respiratory Medicine

Volumn 3, Issue 1, 2009, Pages 37-51

  Spertini, François ^a   Reymond, Christophe ^a   Leimgruber, Annette ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Adjuvant; Adverse event; Allergy; Asthma; Desensitization; IgE; Immunotherapy; Peptide; Tolerance

Indexed keywords

ADJUVANT; ALLERGEN; ALUMINUM HYDROXIDE; CALCIUM PHOSPHATE; DNA VACCINE; GAMMA INTERFERON; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; OLIGODEOXYNUCLEOTIDE; PLACEBO; POLLEN ANTIGEN; POLLINEX QUATRO; QBG10; RAGWEED ANTIGEN; STEROID; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ALLERGY; ANAPHYLAXIS; ANTIGEN SPECIFICITY; ASTHMA; CELL MATURATION; CLINICAL TRIAL; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE COURSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; REGULATORY T LYMPHOCYTE; REVIEW; SENSITIZATION; STANDARDIZATION; TH1 CELL; TH2 CELL; TREATMENT DURATION;

EID: 70149112819     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.3.1.37     Document Type: Review

References (133)

1. + dendritic cells during allergen challenge abrogates the characteristic features of asthma. J. Exp. Med. 201(6), 981-991 (2005).
2. Hammad H, Lambrecht BN. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nat. Rev. Immunol. 8(3), 193-204 (2008).
3. Walley AJ, Wiltshire S, Ellis CM, Cookson WO. Linkage and allelic association of chromosome 5 cytokine cluster genetic markers with atopy and asthma associated traits. Genomics 72(1), 15-20 (2001).
4. Renauld JC. New insights into the role of cytokines in asthma. J. Clin. Pathol. 54(8), 577-589 (2001).
5. Shahana S, Bjornsson E, Ludviksdottir D et al. Ultrastructure of bronchial biopsies from patients with allergic and non-allergic asthma. Respir. Med. 99(4), 429-443 (2005).
6. Kay AB. The role of eosinophils in the pathogenesis of asthma. Trends Mol. Med. 11(4), 148-152 (2005).
7. Gangur V, Birmingham NP, Thanesvorakul S, Joseph S. CCR3 and CXCR3 as drug targets for allergy: principles and potential. Curr. Drug Targets Inflamm. Allergy 2(1), 53-62 (2003).
8. Truyen E, Coteur L, Dilissen E et al. Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients. Thorax 61(3), 202-208 (2006).
9. Barczyk A, Pierzchala W, Sozanska E. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir. Med. 97(6), 726-733 (2003).
10. Kolls JK, Kanaly ST, Ramsay AJ. Interleukin-17: an emerging role in lung inflammation. Am. J. Respir. Cell. Mol. Biol. 28(1), 9-11 (2003).
11. Wang YH, Liu YJ. The IL-17 cytokine family and their role in allergic inflammation. Curr. Opin. Immunol. 20(6), 697-702 (2008).
12. Larche M. Regulatory T cells in allergy and asthma. Chest 132(3), 1007-1014 (2007).
13. + regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 363(9409), 608-615 (2004).
14. Holgate ST, Davies DE, Puddicombe S et al. Mechanisms of airway epithelial damage: epithelial-mesenchymal interactions in the pathogenesis of asthma. Eur. Respir. J. 44(Suppl.) S24-S29 (2003).
15. Kay AB, Phipps S, Robinson DS. A role for eosinophils in airway remodelling in asthma. Trends Immunol. 25(9), 477-482 (2004).
16. Bousquet J, Hejjaoui A, Clauzel AM et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J. Allergy Clin. Immunol. 82(6), 971-977 (1988).
17. Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma. J. Allergy Clin. Immunol. 83(4), 797-802 (1989).
18. Holgate ST. Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Cytokine 28(4-5), 152-157 (2004).
19. Berry MA, Hargadon B, Shelley M et al. Evidence of a role of tumor necrosis factor α in refractory asthma. N. Engl. J. Med. 354(7), 697-708 (2006).
20. Watelet JB, Van Zele T, Gjomarkaj M et al. Tissue remodelling in upper airways: where is the link with lower airway remodelling? Allergy 61(11), 1249-1258 (2006).
21. Malling H-J, Weeke B. Position paper: immunotherapy. (EAACI) The European Academy of Allergology and Clinical Immunology. Allergy 48(14 Suppl.), 7-35 (1993).
22. Bousquet J, Michel FB. Specific immunotherapy in asthma: is it effective? J. Allergy Clin. Immunol. 94(1), 1-11 (1994).
23. Bousquet J, Khaltaev N, Cruz AA et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63(Suppl. 86), 8-160 (2008).
24. Noon L. Prophylactic inoculation for hay fever. Lancet 1572-1573 (1911).
25. van Cauwenberge P, Bachert C, Passalacqua G et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 55(2), 116-134 (2000).
26. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J. Allergy Clin. Immunol. 119(4), 780-791 (2007).
27. Jutel M, Akdis CA. T-cell regulatory mechanisms in specific immunotherapy. Chem. Immunol. Allergy 94, 158-177 (2008).
28. James LK, Durham SR. Update on mechanisms of allergen injection immunotherapy. Clin. Exp. Allergy 38(7), 1074-1088 (2008).
29. Akdis CA, Akdis M, Blesken T et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J. Clin. Invest. 98(7), 1676-1683 (1996).
30. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J. Clin. Invest. 102(1), 98-106 (1998).
31. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immunol. 2(8), 725-731 (2001).
32. Jutel M, Akdis M, Budak F et al. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. 33(5), 1205-1214 (2003).
33. Jutel M, Pichler WJ, Skrbic D et al. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures. J. Immunol. 154(8), 4187-4194 (1995).
34. Kämmerer R, Chvatchko Y, Kettner A et al. Modulation of T-cell response to phospholipase A2 and phospholipase A2-derived peptides by conventional bee venom immunotherapy. J. Allergy Clin. Immunol. 100(1), 96-103 (1997).
35. Wachholz PA, Nouri-Aria KT, Wilson DR et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology, 105(1), 56-62 (2002).
36. Hansen G, Berry G, DeKruyff RH, Umetsu DT. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J. Clin. Invest. 103(2), 175-183 (1999).
37. Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY. IgE versus IgG4 production can be differentially regulated by IL-10. J. Immunol. 160(7), 3555-3561 (1998).
38. Francis JN, James LK, Paraskevopoulos G et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J. Allergy Clin. Immunol. 121(5), 1120-1125 E1122 (2008).
39. Meiler F, Zumkehr J, Klunker S et al. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J. Exp. Med. 205(12), 2887-2898 (2008).
40. Wachholz PA, Durham SR. Induction of 'blocking' IgG antibodies during immunotherapy. Clin. Exp. Allergy 33(9), 1171-1174 (2003).
41. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J. Allergy Clin. Immunol. 112(5), 915-922 (2003).
42. Nouri-Aria KT, Wachholz PA, Francis JN et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol. 172(5), 3252-3259 (2004).
43. Van Ree R, Van Leeuwen WA, Dieges PH et al. Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy. Clin. Exp. Allergy 27(1), 68-74 (1997).
44. + T cells by grass pollen immunotherapy. J. Allergy Clin. Immunol. 111(6), 1255-1261 (2003).
45. + cells in the nasal mucosa. J. Allergy Clin. Immunol. 121(6), 1467-1472 (2008).
46. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst. Rev. 4, CD001186 (2003).
47. Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341(7), 468-475 (1999).
48. Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J. Allergy Clin. Immunol. 107(1), 87-93 (2001).
49. Pichler CE, Helbling A, Pichler WJ. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 56(4), 301-306 (2001).
50. Pichler CE, Marquardsen A, Sparholt S et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 52(3), 274-283 (1997).
51. Jacobsen L, Nuchel Petersen B, Wihl JA, Lowenstein H, Ipsen H. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 52(9), 914-920 (1997).
52. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. 109(2), 251-256 (2002).
53. Jacobsen L, Niggemann B, Dreborg S et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62(8), 943-948 (2007).
54. Grembiale RD, Camporota L, Naty S et al. Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness. Am. J. Respir. Crit. Care Med. 162(6), 2048-2052 (2000).
55. Leynaert B, Neukirch C, Kony S et al. Association between asthma and rhinitis according to atopic sensitization in a population-based study. J. Allergy Clin. Immunol. 113(1), 86-93 (2004).
56. Shaaban R, Zureik M, Soussan D et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 372(9643), 1049-1057 (2008).
57. Des Roches A, Paradis L, Menardo JL et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J. Allergy Clin. Immunol. 99(4), 450-453 (1997).
58. Schadlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 17(1), 37-52 (2000).
59. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol. 102(4 Pt 1), 558-562 (1998).
60. Adkinson NF Jr, Eggleston PA, Eney D et al. A controlled trial of immunotherapy for asthma in allergic children. N. Engl. J. Med. 336(5), 324-331 (1997).
61. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma - Summary Report 2007. J. Allergy Clin. Immunol. 120(5 Suppl.), S94-S138 (2007).
62. Winther L, Arnved J, Malling HJ, Nolte H, Mosbech H. Side-effects of allergen-specific immunotherapy: a prospective multi-centre study. Clin. Exp. Allergy 36(3), 254-260 (2006).
63. Winther L, Malling HJ, Mosbech H. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects. Allergy 55(9), 827-835 (2000).
64. Leynadier F, Banoun L, Dollois B et al. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study. Clin. Exp. Allergy 31(7), 988-996 (2001).
65. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst. Rev. 2, CD002893 (2003).
66. Bousquet PJ, Demoly P, Passalacqua G, Canonica GW, Bousquet J. Immunotherapy: clinical trials - optimal trial and clinical outcomes. Curr. Opin. Allergy Clin. Immunol. 7(6), 561-566 (2007).
67. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 117(4), 802-809 (2006).
68. Pajno GB, Passalacqua G, Vita D et al. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. Allergy 59(8), 883-887 (2004).
69. Di Rienzo V, Marcucci F, Puccinelli P et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin. Exp. Allergy 33(2), 206-210 (2003).
70. Novembre E, Galli E, Landi F et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 114(4), 851-857 (2004).
71. Marogna M, Tomassetti D, Bernasconi A et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann. Allergy Asthma Immunol. 101(2), 206-211 (2008).
72. Andre C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual-swallow immunotherapy in children and adults. Int. Arch. Allergy Immunol. 121(3), 229-234 (2000).
73. Rodriguez-Perez N, Ambriz-Moreno Mde J, Canonica GW, Penagos M. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann. Allergy Asthma Immunol. 101(3), 304-310 (2008).
74. Dahl R, Kapp A, Colombo G et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J. Allergy Clin. Immunol. 121(2), 512-518 e512 (2008).
75. Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 61(10), 1162-1172 (2006).
76. Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 118(2), 434-440 (2006).
77. Marogna M, Spadolini I, Massolo A et al. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Ann. Allergy Asthma Immunol. 98(3), 274-280 (2007).
78. Passalacqua G, Musarra A, Pecora S et al. Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY project: evaluation of a novel SLIT formulation during a year). Pediatr. Allergy Immunol. 18(1), 58-62 (2007).
79. Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J. Allergy Clin. Immunol. 119(4), 881-891 (2007).
80. Jutel M, Jaeger L, Suck R et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J. Allergy Clin. Immunol. 116(3), 608-613 (2005).
81. Pauli G, Larsen TH, Rak S et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 122(5), 951-960 (2008).
82. Lee TM, Grammer LC, Shaughnessy MA, Patterson R. Modified antigens in the treatment of allergic disease. Year Immunol. 2, 338-350 (1986).
83. Bousquet J, Hejjaoui A, Soussana M, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. J. Allergy Clin. Immunol. 85(2), 490-497 (1990).
84. Bousquet J, Maasch HJ, Hejjaoui A et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma. J. Allergy Clin. Immunol. 84(4 Pt 1), 546-556 (1989).
85. Wurtzen PA, Lund L, Lund G et al. Chemical modification of birch allergen extract leads to a reduction in allergenicity as well as immunogenicity. Int. Arch. Allergy Immunol. 144(4), 287-295 (2007).
86. Henmar H, Lund G, Lund L, Petersen A, Wurtzen PA. Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy. Clin. Exp. Immunol. 153(3), 316-323 (2008).
87. Ferreira F, Ebner C, Kramer B et al. Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J. 12(2), 231-242 (1998).
88. Swoboda I, De Weerd N, Bhalla PL et al. Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. Eur. J. Immunol. 32(1), 270-280 (2002).
89. Wallner M, Stocklinger A, Thalhamer T et al. Allergy multivaccines created by DNA shuffling of tree pollen allergens. J. Allergy Clin. Immunol. 120(2), 374-380 (2007).
90. Kussebi F, Karamloo F, Rhyner C et al. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J. Allergy Clin. Immunol. 115(2), 323-329 (2005).
91. Niederberger V, Horak F, Vrtala S et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl Acad. Sci. USA 101(Suppl. 2), 14677-14682 (2004).
92. Pauli G, Purohit A, Oster JP et al. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population. Clin. Exp. Allergy 30(8), 1076-1084 (2000).
93. Niederberger V, Reisinger J, Valent P et al. Vaccination with genetically modified birch pollen allergens: immune and clinical effects on oral allergy syndrome. J. Allergy Clin. Immunol. 119(4), 1013-1016 (2007).
94. Reisinger J, Horak F, Pauli G et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J. Allergy Clin. Immunol. 116(2), 347-354 (2005).
95. Gafvelin G, Thunberg S, Kronqvist M et al. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int. Arch. Allergy Immunol. 138(1), 59-66 (2005).
96. urohit A, Niederberger V, Kronqvist M et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin. Exp. Allergy 38(9), 1514-1525 (2008).
97. Norman PS, Ohman JL Jr, Long AA et al. Treatment of cat allergy with T-cell reactive peptides. Am. J. Respir. Crit. Care Med. 154(6 Pt 1), 1623-1628 (1996).
98. Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin. Immunol. 93(3), 222-231 (1999).
99. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomized controlled trial. Lancet 360(9326), 47-53 (2002).
100. + T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin. Exp. Allergy 35(1), 52-58 (2005).
101. Oldfield WL, Kay AB, Larche M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J. Immunol. 167(3), 1734-1739 (2001).
102. Haselden BM, Larche M, Meng Q et al. Late asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or T(H)2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid. J. Allergy Clin. Immunol. 108(3), 394-401 (2001).
103. Alexander C, Tarzi M, Larche M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 60(10), 1269-1274 (2005).
104. + T cells: a double-blind placebo-controlled study. Allergy 59(10), 1097-1101 (2004).
105. + T cell population with regulatory activity. PLoS Med. 2(3), e78 (2005).
106. Muller U, Akdis CA, Fricker M et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 101(6 Pt 1), 747-754 (1998).
107. Fellrath J-M, Kettner A, Dufour N et al. Allergen specific T cell tolerance induction with allergen-derived long peptides: results of a Phase I safety and immunogenicity trial. J. Allergy Clin. Immunol. 111, 854-861 (2003).
108. Corradin G, Spertini F, Verdini A. Medicinal application of long synthetic peptide technology. Expert Opin. Biol. Ther. 4(10), 1629-1639 (2004).
109. Audran R, Cachat M, Lurati F et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect. Immun. 73(12), 8017-8026 (2005).
110. Sato Y, Roman M, Tighe H et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273(5273), 352-354 (1996).
111. Spiegelberg HL, Tighe H, Roman M, Broide D, Raz E. Inhibition of IgE formation and allergic inflammation by allergen gene immunization and by CpG motif immunostimulatory oligodeoxynucleotides. Allergy 53(45 Suppl.), 93-97 (1998).
112. Jilek S, Barbey C, Spertini F, Corthesy B. Antigen-independent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice. J. Immunol. 166(5), 3612-3621 (2001).
113. Lemieux P. Technological advances to increase immunogenicity of DNA vaccines. Expert Rev. Vaccines 1(1), 85-93 (2002).
114. Santeliz JV, Van Nest G, Traquina P, Larsen E, Wills-Karp M. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J. Allergy Clin. Immunol. 109(3), 455-462 (2002).
115. Marshall JD, Abtahi S, Eiden JJ et al. Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J. Allergy Clin. Immunol. 108(2), 191-197 (2001).
116. Tighe H, Takabayashi K, Schwartz D et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 106(1 Pt 1), 124-134 (2000).
117. Tulic MK, Fiset PO, Christodoulopoulos P et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol. 113(2), 235-241 (2004).
118. Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol. 113(6), 1144-1151 (2004).
119. Creticos PS, Schroeder JT, Hamilton RG et al. Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 355(14), 1445-1455 (2006).
120. Kline JN. Immunotherapy of asthma using CpG oligodeoxynucleotides. Immunol. Res. 39(1-3), 279-286 (2007).
121. DeFrancesco L. Dynavax trial halted. Nat. Biotechnol. 26(5), 484 (2008).
122. McCormack PL, Wagstaff AJ. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro). Drugs 66(7), 931-938 (2006).
123. Baldrick P, Richardson D, Woroniecki SR, Lees B. Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy. J. Appl. Toxicol. 27(4), 399-409 (2007).
124. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56(6), 498-505 (2001).
125. Mothes N, Heinzkill M, Drachenberg KJ et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin. Exp. Allergy 33(9), 1198-1208 (2003).
126. Pearce N, Ait-Khaled N, Beasley R et al. Worldwide trends in the prevalence of asthma symptoms: Phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 62(9), 758-766 (2007).
127. Beasley R. The Global Burden of Asthma Report, Global Initiative for Asthma (GINA) (2004).
128. Seymour SM, Chowdhury BA. Immunotherapy with a ragweed vaccine. N. Engl. J. Med. 356(1), 86 (2007).
129. Larche M. Update on the current status of peptide immunotherapy. J. Allergy Clin. Immunol. 119(4), 906-909 (2007).
130. Pauli G, Malling H, Rak S et al. Clinical efficacy of subcutaneous immunotherapy in birch pollen allergic patients: a randomized, double-blind, placebo-controlled study with recombinant Bet v 1 versus natural Bet v 1 or standardized birch extract. Valenta R, Akdis C, Bohle B (Eds). 25th Congress of the European Academy of Allergology and Clinical Immunology. Vienna, Austria, 14-16 June 2006 (Abstract 83).
131. Pizza M, Giuliani MM, Fontana MR et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19(17-19), 2534-2541 (2001).
132. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 26(26), 3197-3208 (2008).
133. Holland D, Booy R, De Looze F et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 198(5), 650-658 (2008).